To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.
Clinical trial NCT03514901 · UNKNOWN
Trial details
- NCT number
- NCT03514901
- Sponsor
- Intergruppo Melanoma Italiano
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-18
- Primary completion
- 2023-04-29
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.